RxDoctor Payments Data

John Philip Markovic, MD

Internal Medicine · Niles, MINPI 1770903189

Payments from drug & device makers

$1,498in general payments, 2019–2025

Across 51 payments — averaging $29.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$306
  • Terumo Medical Corporation$260
  • Novartis$179
  • Pfizer$155
  • AstraZeneca$130
  • Medtronic$115
  • plus $352 from 7 others

What the payments were for

  • Food & beverage$95864%
  • Education$54036%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,498 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$213,612
Medicare patients
999
Services billed
2,930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban743$839,522
XareltoRivaroxaban189$212,568
EntrestoSacubitril/Valsartan159$154,239
Repatha SureclickEvolocumab58$39,500
JardianceEmpagliflozin13$22,343
BrilintaTicagrelor14$13,552
Metoprolol Succinate935$12,069
FarxigaDapagliflozin Propanediol15$10,144
Atorvastatin Calcium785$8,797
Losartan Potassium535$5,435
Amiodarone Hcl136$4,513
Diltiazem 24hr Er (Cd)Diltiazem Hcl150$4,308
Bumetanide104$3,886
Metoprolol Tartrate466$3,748
Torsemide145$3,483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$155$839,522743 claims
NovartisEntresto$179$154,239159 claims
AstraZenecaBrilinta, Farxiga$130$23,69629 claims
Boehringer IngelheimJardiance$17$22,34313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Niles

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →